Reed Jobs: GLP-1 Drugs Could Become a Weapon Against Cancer

Reed Jobs' oncology venture firm Yosemite has surpassed the $350 million target for its second funding round — and its founder is betting that GLP-1 weight-loss drugs will do as much for cancer as any experimental vaccine.

Jobs, son of the late Apple cofounder Steve Jobs, told Fortune's Allie Garfinkle in a recent Term Sheet interview that GLP-1s rank among "the most impactful drugs that we've ever made." His argument rests on a simple chain: GLP-1s reduce obesity, and obesity raises the risk of 13 types of cancer, according to the CDC.

"I think these are going to be some of the most important drugs we've ever actually seen come to market," Jobs said. "[They're] not only going to help people who are obese and struggling with that, but with cancer, with cardiovascular disease, with a lot of things."

How big is the cancer problem?

The American Cancer Society projects 2.1 million Americans will be diagnosed with cancer this year. More than 626,000 will die from the disease — roughly 1,700 people every day.

The CDC estimates that cancers associated with obesity account for 40% of all U.S. cancer diagnoses each year. That includes colon, pancreatic, kidney and breast cancer.

What does the evidence say?

Jobs compared obesity to smoking: the longer a person lives with either risk factor, the greater the odds of developing certain cancers. The comparison comes with a gap in magnitude. A 2024 ACA study found smoking caused an estimated 19.3% of U.S. cancer cases, against 7.6% linked to excess body weight — roughly 2.5 times the attributable share.

"The more time you spend being obese, the greater your odds of getting an obesity-related disease are," he said. "[GLP-1s] are a fantastic way for obese people to basically stop being obese very quickly."

Some research supports the thesis. A study published in JAMA Oncology last year followed 86,632 adults eligible for antiobesity medications. GLP-1 users showed a 17% lower "hazard" of developing the 14 cancers studied over time than nonusers.

That is an association, not proof of prevention — and Jobs himself conceded the drugs carry drawbacks, including muscle loss. He still called their rise the biggest biotechnology breakthrough of the past three years.

Why does a VC run by Steve Jobs' son care?

Reed Jobs started working in cancer labs and studied pre-med at Stanford after his father was diagnosed with pancreatic cancer in 2003. He has described curing the disease as his life's work, a pursuit that led him to found Yosemite, his oncology-focused venture capital firm.

While he is excited by experimental cancer vaccines, GLP-1s are where he sees the nearer-term payoff. The firm's second funding round crossing its $350 million target gives him capital to act on that conviction.

Can cancer actually be cured?

Jobs said no — at least not entirely. Human cells always carry some risk of becoming cancerous, making total eradication unrealistic in his view.

His model is HIV: a once-fatal diagnosis now managed with medication.

"It's the victory over death, and that is what I want for cancer patients, and I think that that's more achievable and more realistic," Jobs said.

For a $350 million-plus fund, that framing matters: management, not cure, may be where the returns — and the patients — are.